Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (121-130 of 459) with videos related to

Pageof 46
Sort By:
European Urology|October 4, 2015
Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3Matteo Santoni, Marina Scarpelli, Antonio Lopez-Beltran, et al.
Oncotarget|December 8, 2016
Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent mannerMaria Beatrice Morelli, Consuelo Amantini, Massimo Nabissi, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|September 24, 2022
Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterationsJavier Pozas, Teresa Alonso-Gordoa, Maria San Román, et al.
Clinical Genitourinary Cancer|August 28, 2014
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature dataRoberto Iacovelli, Matteo Santoni, Elena Verzoni, et al.
Translational Andrology and Urology|April 14, 2021
Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, et al.
Cells|April 30, 2020
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate CancerRodolfo Montironi, Alessia Cimadamore, Antonio Lopez-Beltran, et al.
Frontiers in Oncology|April 12, 2019
Microbiome and Cancers, With Focus on Genitourinary TumorsAlessia Cimadamore, Matteo Santoni, Francesco Massari, et al.
Translational Andrology and Urology|April 14, 2021
Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United StatesMatteo Santoni, Alessia Cimadamore, Francesco Massari, et al.
Clinical Drug Investigation|January 30, 2020
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of PatientsVincenzo Di Nunno, Matteo Santoni, Veronica Mollica, et al.
Current Drug Targets|March 26, 2020
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 AssayAlessia Cimadamore, Francesco Massari, Matteo Santoni, et al.
Pageof 46

Showing results (121-130 of 459) with videos related to

Sort By:
Pageof 46
European Urology|October 4, 2015
Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3Matteo Santoni, Marina Scarpelli, Antonio Lopez-Beltran, et al.
Oncotarget|December 8, 2016
Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent mannerMaria Beatrice Morelli, Consuelo Amantini, Massimo Nabissi, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|September 24, 2022
Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterationsJavier Pozas, Teresa Alonso-Gordoa, Maria San Román, et al.
Clinical Genitourinary Cancer|August 28, 2014
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature dataRoberto Iacovelli, Matteo Santoni, Elena Verzoni, et al.
Translational Andrology and Urology|April 14, 2021
Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, et al.
Cells|April 30, 2020
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate CancerRodolfo Montironi, Alessia Cimadamore, Antonio Lopez-Beltran, et al.
Frontiers in Oncology|April 12, 2019
Microbiome and Cancers, With Focus on Genitourinary TumorsAlessia Cimadamore, Matteo Santoni, Francesco Massari, et al.
Translational Andrology and Urology|April 14, 2021
Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United StatesMatteo Santoni, Alessia Cimadamore, Francesco Massari, et al.
Clinical Drug Investigation|January 30, 2020
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of PatientsVincenzo Di Nunno, Matteo Santoni, Veronica Mollica, et al.
Current Drug Targets|March 26, 2020
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 AssayAlessia Cimadamore, Francesco Massari, Matteo Santoni, et al.
Pageof 46